Evaxion Biotech A/S
EVAXNASDAQHealthcare● Active
$3.73
+$0.18(+5.07%)
Market Cap$23560814
P/E Ratio—
52W High$12.15
52W Low$2.07
Evaxion Biotech A/S (EVAX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
EVAX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.44
Est. -$0.01 · -4300.0%
Revenue
—
Est. $0.01B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS
EVAX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.01 | — | — | — | $0.01B | — |
| ▼ Q2 FY2026 | May 7, 2026 | -$0.01 | -$0.44 | -4300.0% | — | $0.01B | — |
| ▼ Q1 FY2026 | Mar 5, 2026 | -$0.24 | -$1.00 | -308.2% | — | $0.01B | — |
| — Q4 FY2025 | Nov 6, 2025 | — | $0.73 | — | $0.01B | — | — |
| ▼ Q3 FY2025 | Aug 14, 2025 | -$0.50 | -$0.76 | -52.0% | $0.00B | $0.01B | -99.5% |
| ▲ Q2 FY2025 | May 27, 2025 | -$0.65 | -$0.29 | +55.4% | — | $0.00B | — |
| ▼ Q1 FY2025 | Mar 26, 2025 | -$0.26 | -$0.80 | -207.7% | $0.00B | $0.00B | -92.7% |
| ▲ Q4 FY2024 | Oct 31, 2024 | -$0.60 | -$0.20 | +66.7% | $0.00B | $0.00B | +81.8% |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.01
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
-$0.44
EPS Est.
-$0.01
EPS Surpr.
-4300.0%
Revenue
—
Q1 FY2026
Mar 5, 2026Miss
EPS Actual
-$1.00
EPS Est.
-$0.24
EPS Surpr.
-308.2%
Revenue
—
Q4 FY2025
Nov 6, 2025
EPS Actual
$0.73
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
-$0.76
EPS Est.
-$0.50
EPS Surpr.
-52.0%
Revenue
$0.00B
Q2 FY2025
May 27, 2025Beat
EPS Actual
-$0.29
EPS Est.
-$0.65
EPS Surpr.
+55.4%
Revenue
—
Q1 FY2025
Mar 26, 2025Miss
EPS Actual
-$0.80
EPS Est.
-$0.26
EPS Surpr.
-207.7%
Revenue
$0.00B
Q4 FY2024
Oct 31, 2024Beat
EPS Actual
-$0.20
EPS Est.
-$0.60
EPS Surpr.
+66.7%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2031 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q4 FY2030 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q3 FY2030 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q2 FY2030 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q1 FY2030 | $-1.96 | $-1.96 | $-1.96 | 1 |
| Q4 FY2029 | $-0.01 | $-0.01 | $-0.01 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2031 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2030 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2030 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2030 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2030 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2029 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -4300.0% | $4.41 | $4.07 | -7.71% |
| ▼ Q1 FY2026 | Mar 5, 2026 | -308.2% | $3.11 | $3.40 | +9.32% |
| — Q4 FY2025 | Nov 6, 2025 | — | $5.66 | $6.26 | +10.60% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -52.0% | $3.04 | $2.86 | -5.92% |
| ▲ Q2 FY2025 | May 27, 2025 | +55.4% | $1.88 | $2.36 | +25.53% |
| ▼ Q1 FY2025 | Mar 26, 2025 | -207.7% | $1.75 | $1.77 | +1.14% |
| ▲ Q4 FY2024 | Oct 31, 2024 | +66.7% | $13.80 | $13.35 | -3.26% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -700.0% | $13.53 | $13.76 | +1.70% |
Q2 FY2026-7.71%
Report Date
May 7, 2026
EPS Beat/Miss
-4300.0%
Price Before
$4.41
Price After
$4.07
Q1 FY2026+9.32%
Report Date
Mar 5, 2026
EPS Beat/Miss
-308.2%
Price Before
$3.11
Price After
$3.40
Q4 FY2025+10.60%
Report Date
Nov 6, 2025
EPS Beat/Miss
—
Price Before
$5.66
Price After
$6.26
Q3 FY2025-5.92%
Report Date
Aug 14, 2025
EPS Beat/Miss
-52.0%
Price Before
$3.04
Price After
$2.86
Q2 FY2025+25.53%
Report Date
May 27, 2025
EPS Beat/Miss
+55.4%
Price Before
$1.88
Price After
$2.36
Q1 FY2025+1.14%
Report Date
Mar 26, 2025
EPS Beat/Miss
-207.7%
Price Before
$1.75
Price After
$1.77
Q4 FY2024-3.26%
Report Date
Oct 31, 2024
EPS Beat/Miss
+66.7%
Price Before
$13.80
Price After
$13.35
Q3 FY2024+1.70%
Report Date
Aug 14, 2024
EPS Beat/Miss
-700.0%
Price Before
$13.53
Price After
$13.76
Avg Beat Reaction+11.14%
Avg Miss Reaction-0.29%
Beat Rate2 / 8 quarters
Largest Move+25.53% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: EVAX ends December
Evaxion Biotech A/S (EVAX) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.44 — missing the analyst consensus of $-0.01 by -4300.0%. The next EVAX earnings date is expected around September 1, 2026.
Each quarter, investors track EVAX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. EVAX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
EVAX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
EVAX earnings · 5 questionsEvaxion Biotech A/S's next earnings report is expected around September 1, 2026. EVAX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; EVAX historically reports after market close (AMC).
EVAX earnings datewhen is EVAX earningsEVAX next earnings datewhen does EVAX report earningsEVAX earnings calendar
▸ Source: FMP · Evaxion Biotech A/S SEC filings · US GAAP · Evaxion Biotech A/S SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026